York-based life sciences firm Aptamer Group plc announced a contract extension, entailing a new work order, with a “top 5 global” pharmaceutical company.

“As previously announced in the company’s commercial trading update on 6 November 2024, following the successful completion of a project for the development of Optimer binders to support an ELISA assay, Aptamer has now secured an extension to this project,” said the firm.

“This paid-for extension involves the conversion of these binders into a fully functional ELISA assay. This progression demonstrates the efficacy of Aptamer’s Optimer technology in meeting the partner’s requirements and advances the project into assay development.

“Aptamer retains ownership of the intellectual property associated with these binders, positioning the Company to potentially establish commercialisation licenses in the future. This extension underscores the Group’s ability to deliver high-quality results that foster ongoing partnerships with leading pharmaceutical companies.”

Aptamer Group CEO Arron Tolley said: “We are delighted to have successfully completed the initial binder development phase for this top 5 pharma partner and to now extend our collaboration into assay conversion.

“This milestone not only validates the performance of our Optimer platform but also highlights its potential for broader applications in diagnostics and therapeutics. Retaining IP ownership provides us with opportunities for future licensing revenues, aligning with our strategy to build long-term value through repeat business and commercialisation pathways.

“We look forward to providing further updates as this and other projects progress.”